[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 36 of about 36
1. Mak HK, Yau KK, Khong PL, Ching AS, Cheng PW, Au-Yeung PK, Pang PK, Wong KC, Chan BP, Alberta Stroke Programme Early CT Score: Hypodensity of >1/3 middle cerebral artery territory versus Alberta Stroke Programme Early CT Score (ASPECTS): comparison of two methods of quantitative evaluation of early CT changes in hyperacute ischemic stroke in the community setting. Stroke; 2003 May;34(5):1194-6
Genetic Alliance. consumer health - Stroke 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The one third middle cerebral artery territory ((1/3) MCA) method and the Alberta Stroke Program Early CT Score (ASPECTS) were used to detect significant early ischemic changes (EIC) on CT brain of acute stroke patients.
  • RESULTS: Significant EIC were present in 11.4% of the scans with the (1/3) MCA method, and 19.4% with ASPECTS.
  • CONCLUSIONS: The (1/3) MCA method was more reliable in detecting significant EIC on CT brain within 6 hours of stroke onset in routine clinical practice, whereas ASPECTS was able to detect significant EIC in a higher proportion of these early scans.
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Cohort Studies. Female. Hong Kong / epidemiology. Humans. Infarction, Middle Cerebral Artery / drug therapy. Infarction, Middle Cerebral Artery / epidemiology. Infarction, Middle Cerebral Artery / radiography. Ischemic Attack, Transient / drug therapy. Ischemic Attack, Transient / epidemiology. Ischemic Attack, Transient / radiography. Male. Middle Aged. Observer Variation. Predictive Value of Tests. Prevalence. Prospective Studies. Reproducibility of Results. Single-Blind Method. Thrombolytic Therapy. Time Factors

  • Genetic Alliance. consumer health - Ischemic stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Stroke. 2003 Oct;34(10):e179; author reply e179 [12970512.001]
  • (PMID = 12690213.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


2. Houvenaeghel G, Lambaudie E, Buttarelli M, Cohen M, Bannier M, Tallet A, Jacquemier J: [Margin status in invasive breast cancer]. Bull Cancer; 2008 Dec;95(12):1161-70
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several predictive factors for local recurrence have been identified and some of them such as margins of resection, radiation therapy, chemotherapy, and hormonotherapy can be modified.
  • The influence of extensive intraductal component on local recurrence risk has been studied.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Ductal, Breast / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19091649.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


3. Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R, Henkin J: Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res; 2003 Nov 15;63(22):7861-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.
  • Methionine aminopeptidase (MetAP)-2 has been suggested as a novel target for cancer therapy because the anticancer agent TNP-470 irreversibly inactivates the catalytic activity of this enzyme.
  • Here we show that a rationally designed reversible MetAP2 inhibitor, A-357300, suppresses tumor growth preclinically without the toxicities observed with TNP-470.
  • We have synthesized this bestatin-type MetAP2 inhibitor with the aid of crystal structures of the enzyme-inhibitor complexes and parallel synthesis.
  • A-357300 induces cytostasis by cell cycle arrest at the G(1) phase selectively in endothelial cells and in a subset of tumor cells, but not in most primary cells of nonendothelial type.
  • A-357300 inhibits angiogenesis both in vitro and in vivo and shows potent antitumor efficacy in carcinoma, sarcoma, and neuroblastoma murine models.
  • These data affirm that MetAP2 plays a pivotal role in cell growth and establish that reversible MetAP2 inhibitors are promising novel cancer therapeutic agents.
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Cell Cycle / drug effects. Cell Division / drug effects. Cornea / blood supply. Cyclohexanes. Drug Design. Endothelium, Vascular / cytology. Endothelium, Vascular / drug effects. Endothelium, Vascular / enzymology. Female. Fibrosarcoma / drug therapy. Fibrosarcoma / enzymology. Humans. Mice. Mice, SCID. Models, Molecular. Neovascularization, Physiologic / drug effects. Neuroblastoma / drug therapy. Neuroblastoma / enzymology. Sesquiterpenes / chemistry. Sesquiterpenes / pharmacology. Sesquiterpenes / toxicity. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14633714.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / A357300; 0 / Antineoplastic Agents; 0 / Chlorobenzenes; 0 / Cyclohexanes; 0 / Protease Inhibitors; 0 / Sesquiterpenes; 129298-91-5 / O-(chloroacetylcarbamoyl)fumagillol; EC 3.4.11.- / Aminopeptidases; EC 3.4.11.18 / methionine aminopeptidase 2; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


Advertisement
4. Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ: Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. ACS Chem Biol; 2009 Mar 20;4(3):221-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity.
  • The FAS-II enoyl reductase ftuFabI has been cloned and expressed, and a series of diphenyl ethers have been identified that are subnanomolar inhibitors of the enzyme with MIC90 values as low as 0.00018 microg mL(-1).
  • The compounds are slow-onset inhibitors of ftuFabI, and the residence time of the inhibitors on the enzyme correlates with their in vivo activity in a mouse model of tularemia infection.
  • Significantly, the rate of breakdown of the enzyme-inhibitor complex is a better predictor of in vivo activity than the overall thermodynamic stability of the complex, a concept that has important implications for the discovery of novel chemotherapeutics that normally rely on equilibrium measurements of potency.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. TRICLOSAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4654-9 [10671494.001]
  • [Cites] Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33 [18457948.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):122-33 [11134934.001]
  • [Cites] Annu Rev Microbiol. 2001;55:305-32 [11544358.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):13106-14 [11792710.001]
  • [Cites] Biochemistry. 2003 Apr 22;42(15):4406-13 [12693936.001]
  • [Cites] J Med Chem. 2003 Apr 24;46(9):1627-35 [12699381.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20851-9 [12606558.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31465-8 [12842889.001]
  • [Cites] J Med Chem. 2004 Jan 29;47(3):509-18 [14736233.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Feb;5(2):146-53 [15043388.001]
  • [Cites] Nat Rev Drug Discov. 2004 Sep;3(9):801-8 [15340390.001]
  • [Cites] J Clin Microbiol. 1985 Aug;22(2):212-5 [4031036.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2107-10 [8953047.001]
  • [Cites] Eur J Biochem. 1996 Dec 15;242(3):689-94 [9022698.001]
  • [Cites] J Clin Microbiol. 1998 Feb;36(2):362-6 [9466742.001]
  • [Cites] Nature. 1998 Aug 6;394(6693):531-2 [9707111.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Mar;43(3):711-3 [10049298.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):383-4 [10201369.001]
  • [Cites] J Mol Biol. 1999 Jul 23;290(4):859-65 [10398587.001]
  • [Cites] Biochemistry. 1999 Sep 21;38(38):12514-25 [10493822.001]
  • [Cites] Nat Rev Microbiol. 2004 Dec;2(12):967-78 [15550942.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2256-68 [15572779.001]
  • [Cites] Annu Rev Biochem. 2005;74:791-831 [15952903.001]
  • [Cites] Curr Drug Targets Infect Disord. 2005 Sep;5(3):297-305 [16181147.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):6792-801 [16272336.001]
  • [Cites] Methods Biochem Anal. 2005;46:1-265 [16350889.001]
  • [Cites] Microbes Infect. 2006 Feb;8(2):561-7 [16239121.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17541-4 [16648134.001]
  • [Cites] J Med Chem. 2006 Jul 27;49(15):4574-80 [16854062.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):730-9 [16888652.001]
  • [Cites] ACS Chem Biol. 2006 Feb 17;1(1):43-53 [17163639.001]
  • [Cites] Curr Top Med Chem. 2007;7(5):489-98 [17346194.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Apr;51(4):1580-1 [17220418.001]
  • [Cites] Antimicrob Agents Chemother. 2007 Oct;51(10):3562-7 [17664324.001]
  • [Cites] Acc Chem Res. 2008 Jan;41(1):11-20 [18193820.001]
  • [Cites] Biochemistry. 2008 Apr 8;47(14):4228-36 [18335995.001]
  • [Cites] Biochemistry. 2008 May 20;47(20):5481-92 [18412369.001]
  • [Cites] Biochemistry. 2000 Jul 4;39(26):7645-50 [10869170.001]
  • (PMID = 19206187.001).
  • [ISSN] 1554-8937
  • [Journal-full-title] ACS chemical biology
  • [ISO-abbreviation] ACS Chem. Biol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U54 AI065357-040031; United States / NIAID NIH HHS / AI / U01 AI070383; United States / NIAID NIH HHS / AI / AI44639; United States / NIAID NIH HHS / AI / AI065357-040031; United States / NIAID NIH HHS / AI / R01 AI044639; United States / NIAID NIH HHS / AI / AI70383; United States / NIAID NIH HHS / AI / U01 AI070383-02; United States / NIAID NIH HHS / AI / AI057158-04; United States / NIAID NIH HHS / AI / U01 AI070383-03; United States / NIAID NIH HHS / AI / R21 AI044639; United States / NIAID NIH HHS / AI / AI070383-03; United States / NIAID NIH HHS / AI / U54 AI065357-04; United States / NIAID NIH HHS / AI / U54 AI057158; United States / NIAID NIH HHS / AI / AI057158; United States / NIAID NIH HHS / AI / U54 AI057158-04; United States / NIAID NIH HHS / AI / AI070383-02; United States / NIAID NIH HHS / AI / R01 AI044639-08; United States / NIAID NIH HHS / AI / U54 AI065357; United States / NIAID NIH HHS / AI / AI044639-08; United States / NIAID NIH HHS / AI / AI065357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Enzyme Inhibitors; 0 / Fatty Acid Synthesis Inhibitors; 0 / Phenyl Ethers; 4NM5039Y5X / Triclosan; EC 1.3.1.9 / Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); EC 6.- / Fatty Acid Synthase, Type II
  • [Other-IDs] NLM/ NIHMS95103; NLM/ PMC2693246
  •  go-up   go-down


5. Qu N, Ignatenko NA, Yamauchi P, Stringer DE, Levenson C, Shannon P, Perrin S, Gerner EW: Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Biochem J; 2003 Oct 15;375(Pt 2):465-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Racemic difluoromethylornithine (D/L-DFMO) is an inhibitor of ODC (ornithine decarboxylase), the first enzyme in eukaryotic polyamine biosynthesis.
  • D/L-DFMO is an effective anti-parasitic agent and inhibitor of mammalian cell growth and development.
  • However, both DFMO enantiomers suppressed ODC activity in a time- and concentration-dependent manner.
  • ODC activity failed to recover after treatment with either L- or D-DFMO and dialysis to remove free inhibitor.
  • The inhibitor dissociation constant (K(D)) values for the formation of enzyme-inhibitor complexes were 28.3+/-3.4, 1.3+/-0.3 and 2.2+/-0.4 microM respectively for D-, L- and D/L-DFMO.
  • The inhibitor inactivation constants (K(inact)) for the irreversible step were 0.25+/-0.03, 0.15+/-0.03 and 0.15+/-0.03 min(-1) respectively for D-, L- and D/L-DFMO.
  • D-DFMO was a more potent inhibitor (IC50 approximately 7.5 microM) when compared with D-ornithine (IC50 approximately 1.5 mM) of ODC-catalysed L-ornithine decarboxylation.
  • Treatment of human colon tumour-derived HCT116 cells with either L- or D-DFMO decreased the cellular polyamine contents in a concentration-dependent manner.
  • Both enantiomers form enzyme-inhibitor complexes with ODC, but the probability of formation of these complexes is 20 times greater for L-DFMO when compared with D-DFMO.
  • The rate of the irreversible reaction in ODC inactivation is similar for the L- and D-enantiomer.
  • This unexpected similarity between DFMO enantiomers, in contrast with the high degree of stereospecificity of the substrate ornithine, appears to be due to the alpha-substituent of the inhibitor.
  • The D-enantiomer may have advantages, such as decreased normal tissue toxicity, over L- or D/L-DFMO in some clinical applications.

  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - Decarboxylases - overview and references .
  • Guide to Pharmacology. gene/protein/disease-specific - Ornithine decarboxylase - data and references .
  • Hazardous Substances Data Bank. Eflornithine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Nov 16;38(46):15174-84 [10563800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7804-8 [8356088.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 May;127(5):553-8 [11346432.001]
  • [Cites] Skin Therapy Lett. 2001 Apr;6(7):1-3, 5 [11376395.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6549-58 [11533243.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):149-55 [11801552.001]
  • [Cites] Mol Carcinog. 2002 May;34(1):10-8 [12112318.001]
  • [Cites] Science. 1980 Oct 17;210(4467):332-4 [6775372.001]
  • [Cites] J Bacteriol. 1980 Dec;144(3):952-6 [7002915.001]
  • [Cites] J Biol Chem. 1993 Nov 25;268(33):24572-9 [8227016.001]
  • [Cites] Acta Trop. 1993 Sep;54(3-4):153-62 [7902654.001]
  • [Cites] J Biol Chem. 1993 Dec 25;268(36):27277-85 [8262968.001]
  • [Cites] J Cell Physiol. 1994 Feb;158(2):237-44 [8106560.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1122-30 [8028034.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):945-51 [10353725.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1709-13 [10469614.001]
  • [Cites] J Biol Chem. 1962 Oct;237:3245-9 [14033211.001]
  • [Cites] J Chromatogr. 1980 Dec 12;221(2):227-35 [7217292.001]
  • [Cites] J Biol Chem. 1983 Feb 25;258(4):2496-500 [6401734.001]
  • [Cites] DNA. 1987 Jun;6(3):179-87 [3595418.001]
  • [Cites] AIDS. 1990 Oct;4(10):1019-21 [2261116.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5872-6 [2062864.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):150-8 [1730582.001]
  • [Cites] Toxicol Sci. 2000 Jul;56(1):124-32 [10869460.001]
  • (PMID = 12859253.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / CA-72008; United States / NCI NIH HHS / CA / CA-95060
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Ornithine Decarboxylase Inhibitors; EC 4.1.1.17 / Ornithine Decarboxylase; ZQN1G5V6SR / Eflornithine
  • [Other-IDs] NLM/ PMC1223689
  •  go-up   go-down


6. Williams P, Sorribas A, Liang Z: New methods to explore marine resources for Alzheimer's therapeutics. Curr Alzheimer Res; 2010 May;7(3):210-3
MedlinePlus Health Information. consumer health - Alzheimer's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New methods to explore marine resources for Alzheimer's therapeutics.
  • Despite the long history of drug discovery from natural sources, the marine environment, which covers 70% of the Earth's surface, is still relatively unexplored.
  • Based on this rationale, we recently began screening extracts derived from marine invertebrate and cyanobacterial samples for BACE-1 inhibitors in a chemiluminescent enzyme-fragment complementation (EFC) assay.
  • Incubation of the extracts active in the EFC assay with BACE1, subsequent isolation of the enzyme-inhibitor complex and then analysis of the small molecule inhibitor by LC-MS rapidly links a chemical structure to biological activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2002 Aug 15;74(16):3963-71 [12199561.001]
  • [Cites] J Neurosci. 2009 Oct 14;29(41):12748-56 [19828785.001]
  • [Cites] J Ethnopharmacol. 2004 Jun;92(2-3):147-62 [15137996.001]
  • [Cites] Nat Rev Neurosci. 2004 Sep;5(9):677-85 [15322526.001]
  • [Cites] Trends Pharmacol Sci. 1991 Oct;12(10):383-8 [1763432.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):829-37 [15602548.001]
  • [Cites] Nat Rev Drug Discov. 2005 Mar;4(3):206-20 [15729362.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Apr 29;44(18):2806-8 [15798987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15370-4 [17030810.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):666-73 [17108984.001]
  • [Cites] Phytomedicine. 2007 Apr;14(4):289-300 [17346955.001]
  • [Cites] J Nat Prod. 2007 Mar;70(3):461-77 [17309302.001]
  • [Cites] Chembiochem. 2007 May 7;8(7):788-98 [17429823.001]
  • [Cites] J Exp Biol. 2007 Jun;210(Pt 11):1992-9 [17515424.001]
  • [Cites] J Biomol Screen. 2008 Apr;13(4):265-75 [18349420.001]
  • [Cites] Nat Rev Drug Discov. 2009 Jan;8(1):69-85 [19096380.001]
  • [Cites] Alzheimers Dement. 2009 May;5(3):234-70 [19426951.001]
  • [Cites] Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):97-104 [15090161.001]
  • (PMID = 20088803.001).
  • [ISSN] 1875-5828
  • [Journal-full-title] Current Alzheimer research
  • [ISO-abbreviation] Curr Alzheimer Res
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P50 ES012740; United States / NIEHS NIH HHS / ES / ES012740-05; United States / NIA NIH HHS / AG / R21 AG032405; United States / NIEHS NIH HHS / ES / P50 ES012740-05; United States / NIA NIH HHS / AG / 1R21AG032405; United States / NIA NIH HHS / AG / AG032405-01A1; United States / NIA NIH HHS / AG / R21 AG032405-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human
  • [Number-of-references] 20
  • [Other-IDs] NLM/ NIHMS310317; NLM/ PMC3170562
  •  go-up   go-down


7. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C: Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother; 2006 Mar;50(3):899-909
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
  • VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC50 = 280 nM).
  • VX-950 forms a covalent but reversible complex with the genotype 1a HCV NS3-4A protease in a slow-on, slow-off process with a steady-state inhibition constant (K(i)*) of 7 nM.
  • Dissociation of the covalent enzyme-inhibitor complex of VX-950 and genotype 1a HCV protease has a half-life of almost an hour.
  • A >4-log10 reduction in the HCV RNA levels was observed after a 2-week incubation of replicon cells with VX-950, with no rebound of viral RNA observed after withdrawal of the inhibitor.
  • In a recently developed HCV protease mouse model, VX-950 showed excellent inhibition of HCV NS3-4A protease activity in the liver.
  • Therefore, the overall preclinical profile of VX-950 supports its candidacy as a novel oral therapy against hepatitis C.
  • [MeSH-minor] Administration, Oral. Animals. Area Under Curve. Binding Sites. Biological Availability. Cell Line. Cells, Cultured. Dogs. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Half-Life. Hepatocytes / drug effects. Humans. Inhibitory Concentration 50. Male. Mice. Mice, SCID. RNA, Viral / physiology. Rats. Rats, Inbred F344. Rats, Sprague-Dawley. Replicon / physiology. Substrate Specificity

  • Genetic Alliance. consumer health - Hepatitis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1997 Aug 5;36(31):9340-8 [9235976.001]
  • [Cites] J Gen Virol. 1997 Jan;78 ( Pt 1):39-43 [9010283.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):4843-54 [9478925.001]
  • [Cites] Science. 1998 Oct 2;282(5386):103-7 [9756471.001]
  • [Cites] Science. 1999 Jul 2;285(5424):110-3 [10390360.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1347-55 [15521004.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Dec;48(12):4784-92 [15561857.001]
  • [Cites] Hepatology. 2005 Apr;41(4):832-5 [15732092.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36784-91 [16087668.001]
  • [Cites] J Virol. 2000 Feb;74(4):2046-51 [10644379.001]
  • [Cites] Biochemistry. 2000 Feb 22;39(7):1849-61 [10677236.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):7152-7 [10702283.001]
  • [Cites] Semin Liver Dis. 2000;20(1):1-16 [10895428.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] J Viral Hepat. 2002 Mar;9(2):84-100 [11876790.001]
  • [Cites] J Virol. 2002 Aug;76(16):8189-99 [12134024.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S3-20 [12407572.001]
  • [Cites] J Virol. 2003 Mar;77(6):3669-79 [12610142.001]
  • [Cites] Antiviral Res. 2003 Mar;58(1):1-16 [12719002.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Nov 17;13(22):4059-63 [14592508.001]
  • [Cites] Nature. 2003 Nov 13;426(6963):186-9 [14578911.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):251-6 [14684337.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):257-61 [14684338.001]
  • [Cites] Ann Intern Med. 2004 Mar 2;140(5):346-55 [14996676.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Mar 22;14(6):1441-6 [15006379.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Apr 19;14(8):1939-42 [15050632.001]
  • [Cites] Hepatology. 2004 Apr;39(4):1147-71 [15057920.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17508-14 [14766754.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2260-6 [15155230.001]
  • [Cites] J Virol. 2004 Jul;78(14):7352-9 [15220408.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Aug 16;14(16):4333-8 [15261297.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Oct 4;14(19):5007-11 [15341970.001]
  • [Cites] Biochim Biophys Acta. 1969;185(2):269-86 [4980133.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] J Virol. 1993 May;67(5):2832-43 [8386278.001]
  • [Cites] J Virol. 1995 Jul;69(7):4373-80 [7769699.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7622-6 [7644466.001]
  • [Cites] Anal Biochem. 1996 Aug 15;240(1):60-7 [8811880.001]
  • [Cites] Cell. 1996 Oct 18;87(2):343-55 [8861917.001]
  • [Cites] Hepatology. 1997 Nov;26(5):1328-37 [9362380.001]
  • (PMID = 16495249.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / RNA, Viral; 0 / Serine Proteinase Inhibitors; 655M5O3W0U / telaprevir
  • [Other-IDs] NLM/ PMC1426435
  •  go-up   go-down


8. Patel SC, Levine SR, Tilley BC, Grotta JC, Lu M, Frankel M, Haley EC Jr, Brott TG, Broderick JP, Horowitz S, Lyden PD, Lewandowski CA, Marler JR, Welch KM, National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA; 2001 Dec 12;286(22):2830-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
  • CONTEXT: The prevalence and clinical significance of early ischemic changes (EICs) on baseline computed tomography (CT) scan of the head obtained within 3 hours of ischemic stroke are not established.
  • OBJECTIVE: To determine the frequency and significance of EIC on baseline head CT scans in the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA (recombinant tissue plasminogen activator) Stroke Trial.
  • For the current analysis, detailed reevaluation was undertaken after October 1994 of all baseline head CT scans with clinical data available pretreatment (blinded to treatment arm).
  • MAIN OUTCOME MEASURES: Frequency of EICs on baseline CT scans; association of EIC with other baseline variables; effect of EICs on deterioration at 24 hours (>/=4 points increase from the baseline National Institutes of Health Stroke Scale [NIHSS] score); clinical outcome (measured by 4 clinical scales) at 3 months, CT lesion volume at 3 months, death at 90 days; and symptomatic intracranial hemorrhage (ICH) within 36 hours of treatment.
  • RESULTS: The prevalence of EIC on baseline CT in the combined rt-PA and placebo groups was 31% (n = 194).
  • The EIC was significantly associated with baseline NIHSS score (rho = 0.23; P<.001) and time from stroke onset to baseline CT scan (rho = 0.11; P =.007).
  • After adjusting for baseline variables, there was no EIC x treatment interaction detected for any clinical outcome, including deterioration at 24 hours, 4 clinical scales, lesion volume, and death at 90 days (P>/=.25), implying that EIC is unlikely to affect response to rt-PA treatment.
  • After adjusting for NIHSS score (an independent predictor of ICH), no EIC association with symptomatic ICH at 36 hours was detected in the group treated with rt-PA (P>/=.22).
  • CONCLUSIONS: Our analysis suggests that EICs are prevalent within 3 hours of stroke onset and correlate with stroke severity.
  • However, EICs are not independently associated with increased risk of adverse outcome after rt-PA treatment.
  • Patients treated with rt-PA did better whether or not they had EICs, suggesting that EICs on CT scan are not critical to the decision to treat otherwise eligible patients with rt-PA within 3 hours of stroke onset.

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - Ischemic Stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2002 May 8;287(18):2361-2; author reply 2362 [11988052.001]
  • (PMID = 11735758.001).
  • [ISSN] 0098-7484
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; EC 3.4.21.- / Plasminogen Activators; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


9. Freedman GM, Hanlon AL, Fowble BL, Anderson PR, Nicolaou N: Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast-conserving surgery and radiation. J Clin Oncol; 2002 Oct 1;20(19):4015-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Recursive partitioning analysis (RPA), a method of building decision trees of significant prognostic factors for outcome, was used to determine subgroups at significantly different risk for ipsilateral breast tumor recurrence (IBTR) in early-stage breast cancer.
  • Systemic therapy was chemotherapy with or without tamoxifen in 32%, tamoxifen in 27%, or none in 41%.
  • RPA was used to create a decision tree according to predictive variables that classify patients by IBTR risk, and the Kaplan-Meier method was used to calculate 10-year risks.
  • For patients </= 55 years old, extensive intraductal component (EIC) was the next significant split.
  • For EIC-negative tumors, age </= 35 years and negative margins were associated with a 10-year IBTR of 3%; with close (</= 2 mm) or positive margins, 34%.
  • Patients </= 35 years old had a low risk of IBTR when tumors were EIC-negative with negative margins.
  • EIC was an independent factor for IBTR for ages </= 55 years.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / therapy. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Actuarial Analysis. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Decision Trees. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Prognosis. Risk Assessment. Tamoxifen / administration & dosage

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol 2002 Dec 15;20(24):4727. Nicoloau N [corrected to Nicolaou N]
  • (PMID = 12351599.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


10. Yuan J, Zhang Z, Xiao JY: [Efficacy of radiotherapy combined with Traditional Chinese medicine (TCM) in NPC patients]. Hunan Yi Ke Da Xue Xue Bao; 2000 Jun 28;25(3):254-6
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From January 1992 to November 1994, 163 patients with nasopharyngeal carcinoma (NPC) were prospectively randomized into three groups: standard radiotherapy (SRT) group, external irradiation and after-load intracavitary radiation in combination with traditional Chinese medicine (EIAIRC) group, and external irradiation plus traditional Chinese medicine (EIC) group.
  • The nasopharynx's radiation dose was 50-60 Gy, intracavitary irradiation 16 Gy/2 times (The distance from radiation source to spot of reference was 14 mm away).
  • The radiation dose in EIC and SRT group was 68-72 Gy, respectively.
  • It indicates that the therapy might decrease radiation dose and the TCM does not induce NPC distant metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Cobalt Radioisotopes / therapeutic use. Drugs, Chinese Herbal / therapeutic use. Nasopharyngeal Neoplasms / radiotherapy. Phytotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Female. Humans. Male. Middle Aged. Plants, Medicinal. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12212157.001).
  • [ISSN] 1000-5625
  • [Journal-full-title] Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University
  • [ISO-abbreviation] Hunan Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes; 0 / Drug Combinations; 0 / Drugs, Chinese Herbal
  •  go-up   go-down


11. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M: An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. Breast Cancer; 2002;9(2):145-52
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer.
  • BACKGROUND: The usefulness of primary chemotherapy has been widely recognized and applied to routine clinical practice to improve prognosis by downstaging.
  • Nevertheless, none of many trials has been able to show a positive effect of primary chemotherapy in terms of prognosis, and predictive factors of outcome have not been defined and are still under investigation.
  • METHODS: Primary chemotherapy was given to 50 patients with advanced breast cancer.
  • Predictive factors involved in clinical or pathological response to primary chemotherapy (3 cycles of CE(F) therapy ) were investigated.
  • MIB-1 was related to the clinical response and EIC (extensive intraductal component) was related to the pathological response; the response was high in patients with EIC negative tumors.
  • Responders had tumors with higher proliferative activity, which decreased significantly after chemotherapy.
  • Patients with a decrease of more than 30% in proliferative activity after chemotherapy had significantly higher disease-free survival rates.
  • CONCLUSION: The proliferative activity and EIC status were useful predictors of clinical or pathological response to primary chemotherapy.
  • A decrease in proliferative activity by chemotherapy significantly correlated with clinical response and reflected a favorable prognosis.
  • The number of patients benefiting from primary chemotherapy might steadily increase by detecting these predictive factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Cyclophosphamide / administration & dosage. Cytarabine. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Logistic Models. Mastectomy, Segmental / methods. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Probability. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016394.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; CEF regimen
  •  go-up   go-down


12. Smitt MC, Nowels K, Carlson RW, Jeffrey SS: Predictors of reexcision findings and recurrence after breast conservation. Int J Radiat Oncol Biol Phys; 2003 Nov 15;57(4):979-85
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To identify predictors of reexcision findings and local recurrence in the setting of breast-conserving therapy with radiation.
  • However, the use and sequencing of systemic therapy affected recurrence rates among these patients.
  • For patients with close, positive, or indeterminate margins, the crude risk of local recurrence was 4% among patients who received tamoxifen or received chemotherapy integrated with or after radiation.
  • The risk of local recurrence was 16-29% among the patients with close, positive, or indeterminate margins who did not receive systemic therapy or who received radiation after completion of chemotherapy.
  • Local recurrence rates were low in patients with negative margins (2-8%) regardless of the use of systemic therapy or its timing.
  • Among patients who underwent reexcision before radiation, extensive intraductal component (EIC) (p = 0.0001) and young patient age (p = 0.03) were predictive of residual disease in the specimen.
  • Patients with initially close margins and no EIC had a low risk of residual disease at the time of reexcision, as did patients older than age 65 without EIC.
  • Patient age and EIC were significant predictors of residual disease at reexcision.
  • The use and timing of systemic therapy appear to influence the risk of local recurrence in patients who do not have negative lumpectomy margins.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Multivariate Analysis. Neoplasm, Residual. Reoperation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14575828.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gahn G, Barlinn K, Dzialowski I, Puetz V, Kunz A, Hentschel H, Becker U: Combined thrombolysis with abciximab and rtPA in patients with middle cerebral artery occlusion. Acta Neurol Scand; 2010 Jan;121(1):63-6
Hazardous Substances Data Bank. Abciximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In patients with acute middle cerebral artery (MCA) occlusion, recanalization rates with intravenous (IV) recombinant tissue plasminogen activator (rtPA) are limited.
  • Aim- We evaluated the feasibility and safety of combined IV thrombolysis with abciximab and reduced dose rtPA in a 3- to 6-h time window.
  • METHODS: We prospectively (March 2002 to February 2005) studied patients with symptomatic MCA occlusion on computed tomography (CT) angiography and absence of major early ischemic changes (EIC) on non-contrast CT (NCCT) within 3-6 h from symptom onset.
  • RESULTS: Of 13 patients, mean age was 62 +/- 11 years, onset-to-treatment time 4.8 +/- 0.9 h and median baseline National Institutes of Health Stroke Scale score 11 (interquartile range 6.5-13.5).
  • CONCLUSIONS: In patients with acute symptomatic MCA occlusion and absence of major EIC on NCCT, combined IV thrombolysis with abciximab and half-standard dose rtPA was feasible and seemed to be safe if applied within 3-6 h from symptom onset.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Immunoglobulin Fab Fragments / therapeutic use. Infarction, Middle Cerebral Artery / drug therapy. Platelet Aggregation Inhibitors / therapeutic use. Tissue Plasminogen Activator / therapeutic use
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Pilot Projects. Prospective Studies. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074286.001).
  • [ISSN] 1600-0404
  • [Journal-full-title] Acta neurologica Scandinavica
  • [ISO-abbreviation] Acta Neurol. Scand.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Immunoglobulin Fab Fragments; 0 / Platelet Aggregation Inhibitors; EC 3.4.21.68 / Tissue Plasminogen Activator; X85G7936GV / abciximab
  •  go-up   go-down


14. Behrouzi Z, Khodadoust A: Epithelial iris cyst treatment with intracystic ethanol irrigation. Ophthalmology; 2003 Aug;110(8):1601-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial iris cyst treatment with intracystic ethanol irrigation.
  • PURPOSE: To report the therapeutic effects of ethanol (ETOH) irrigation into epithelial iris cysts (EIC).
  • PARTICIPANTS: 102 eyes of 102 patients aged between 4 and 71 years with EIC, with 4 months to 15 years follow-up.
  • Three types of cysts were identified: single in 88 patients, double in 11 patients, and triple in 3 patients.
  • Of the 102 cases, 3 were excluded from the study because the EIC was connected to the anterior chamber.
  • CONCLUSION: Ethanol irrigation is a cost-effective and safe procedure, and we recommend consideration of the procedure for treatment of iris epithelial cysts.
  • [MeSH-major] Cysts / drug therapy. Ethanol / therapeutic use. Iris Diseases / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Humans. Male. Middle Aged. Pigment Epithelium of Eye / drug effects. Pigment Epithelium of Eye / pathology. Retrospective Studies. Therapeutic Irrigation / methods. Treatment Outcome. Visual Acuity

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12917180.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3K9958V90M / Ethanol
  •  go-up   go-down


15. Schmidt D: [Endometrial carcinomas and precursor lesions--new aspects]. Pathologe; 2009 Jul;30(4):261-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrial carcinomas and precursor lesions--new aspects].
  • Endometrial carcinomas can be separated into two groups which are designated as type I and type II carcinomas today.
  • Only type I carcinomas are associated with hyperestrogenism.
  • The group of type I carcinomas consists of endometrioid carcinoma and its variants, and mucinous carcinoma.
  • The prototypes of type II carcinomas are serous and clear cell carcinoma.
  • Not all carcinomas, however, can be assigned to one of the two groups, because there are hybrid tumors and mixed carcinomas, e.g. endometrioid carcinoma with a serous component.
  • The precursor lesions of the endometrioid carcinoma and the serous carcinoma are well characterized morphologically and by molecular pathology.
  • Atypical hyperplasia is the precursor lesion of endometrioid carcinoma, whereas endometrial intraepithelial carcinoma (EIC) is the precursor lesion of serous carcinoma.
  • No precursor lesion has as yet been identified for clear cell carcinoma.
  • Immunohistochemical markers for endometrial carcinoma are CK7 and vimentin, for serous carcinoma markers are p53 and p16.
  • Correct typing is of essential prognostic necessity in endometrial carcinoma.
  • Of utmost importance is the detection of a serous component, because serous carcinoma leads to early tumor spread with the necessity of radical surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology
  • [MeSH-minor] Biomarkers / analysis. Carcinoma / pathology. Female. Humans. Hyperplasia. Menopause. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4783-91 [17028294.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124 Suppl:S42-51 [16468417.001]
  • [Cites] Pathology. 2007 Feb;39(1):134-8 [17365829.001]
  • [Cites] Adv Anat Pathol. 2002 May;9(3):145-84 [11981113.001]
  • [Cites] Int J Surg Pathol. 2000 Oct;8(4):279-289 [11494005.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):434-40 [9277658.001]
  • [Cites] Cancer. 1985 Jul 15;56(2):403-12 [4005805.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):569-75 [8179072.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):177-85 [9006334.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):287-90 [10684697.001]
  • [Cites] Am J Surg Pathol. 1995 Jul;19(7):769-74 [7793474.001]
  • [Cites] Gynecol Oncol. 1983 Feb;15(1):10-7 [6822361.001]
  • [Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):348-53 [15086736.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):328-33 [17581420.001]
  • [Cites] Pathol Res Pract. 1992 Oct;188(7):856-9 [1448376.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):157-66 [15644772.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17 (2):129-34 [9553809.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1740-7 [8859187.001]
  • [Cites] Pathology. 2007 Feb;39(1):46-54 [17365822.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1561-73 [15785748.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1519-30 [17122507.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):463-9 [14675663.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):37-42 [19116629.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • (PMID = 19495762.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


16. Akashi-Tanaka S, Fukutomi T, Sato N, Miyakawa K: The role of computed tomography in the selection of breast cancer treatment. Breast Cancer; 2003;10(3):198-203
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of computed tomography in the selection of breast cancer treatment.
  • Contrast-enhanced computed tomography (CE-CT) is one of the most sensitive imaging modalities.
  • (1) to determine the extent of breast cancer to select the appropriate breast conserving treatment (BCT).
  • The sensitivity and specificity for the detection of extensive intraductal component (EIC) by CE-CT were 82-88% and 75-89%, respectively.
  • (2) to determine the extent of resection following neoadjuvant chemotherapy, which is difficult to assess by other modalities;.
  • [MeSH-major] Breast Neoplasms / radiography. Tomography, X-Ray Computed / standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12955031.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 32
  •  go-up   go-down


17. Yafune A, Funatogawa T, Ishiguro M: Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation. Stat Med; 2005 Nov 30;24(22):3417-29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extended information criterion (EIC) approach for linear mixed effects models under restricted maximum likelihood (REML) estimation.
  • In clinical data analysis, the restricted maximum likelihood (REML) method has been commonly used for estimating variance components in the linear mixed effects model.
  • We propose an approach using extended information criterion (EIC), which is a bootstrap-based extension of AIC, for comparing linear mixed effects models with different mean and covariance structures under the REML estimation.
  • [MeSH-minor] Biometry. Growth. Humans. Longitudinal Studies. Platelet Count. Purpura, Thrombocytopenic, Idiopathic / blood. Purpura, Thrombocytopenic, Idiopathic / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 John Wiley & Sons, Ltd.
  • (PMID = 16237658.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Li D, Lei YN: [Risk factors for intracerebral hemorrhage after intravenous thrombolysis in acute cerebral infarction]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Oct;15(10):631-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with ESS<60 scores, early ischemic changes (EIC) on cranial CT scans or artrial fibrillation had significantly higher risk of ICH.
  • CONCLUSION: Risk factors associated with ICH are severity of neurological deficit, EIC and artrial fibrillation.
  • [MeSH-major] Cerebral Hemorrhage / etiology. Cerebral Infarction / drug therapy. Thrombolytic Therapy / adverse effects. Urokinase-Type Plasminogen Activator / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Risk Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14552692.001).
  • [ISSN] 1003-0603
  • [Journal-full-title] Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
  • [ISO-abbreviation] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


19. Hatano K, Yokota Y, Hanaki H, Sunakawa K: [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)]. Kansenshogaku Zasshi; 2006 May;80(3):243-50
Hazardous Substances Data Bank. Vancomycin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, the survival rate with combination therapy consistings IPM/CS plus teicoplanin (T EIC) was significantly higher, and the number of residual viable cells in the kidney was significantly lower, than with TEIC monotherapy alone.
  • In the mice with pneumonia, the number of residual viable cells in the lung after combination therapy with IPM/CS and TEIC was significantly lower than with TEIC monotherapy.
  • Combination therapy with beta-lactams plus VCM showed antagonistic in models of systemic infection and pulmonary infection caused by BIVR, whereas combination therapy consisting of a beta-lactam plus TEIC had a synergistic effect in the same models, even though VCM and TEIC are member of the same glycopeptide antibiotic class.
  • [MeSH-major] Staphylococcal Infections / drug therapy. Staphylococcus aureus / drug effects. Teicoplanin / administration & dosage. Vancomycin / administration & dosage. Vancomycin / antagonists & inhibitors. beta-Lactams / administration & dosage. beta-Lactams / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Resistance, Multiple, Bacterial. Male. Methicillin Resistance. Mice. Mice, Inbred ICR

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780131.001).
  • [ISSN] 0387-5911
  • [Journal-full-title] Kansenshōgaku zasshi. The Journal of the Japanese Association for Infectious Diseases
  • [ISO-abbreviation] Kansenshogaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / beta-Lactams; 61036-62-2 / Teicoplanin; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


20. Hetelekidis S, Schnitt SJ, Silver B, Manola J, Bornstein BA, Nixon AJ, Recht A, Gelman R, Harris JR, Connolly JL: The significance of extracapsular extension of axillary lymph node metastases in early-stage breast cancer. Int J Radiat Oncol Biol Phys; 2000 Jan 1;46(1):31-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate if extracapsular extension (ECE) of axillary lymph node metastases predicts for a decreased rate of disease-free survival or an increased rate of regional recurrence of breast carcinoma.
  • METHODS: The study population consisted of 368 patients with T1 or T2 breast cancer and pathologically-positive lymph nodes treated with breast-conserving therapy between 1968 and 1986.
  • Median follow-up time for the surviving patients was 139 months (range 70-244).
  • Twenty percent of the patients were treated with supraclavicular RT, and 64% received both axillary and supraclavicular RT, with a median dose to the nodes of 45 Gy.
  • The following factors were evaluated: presence of ECE, number of sampled lymph nodes (LN), number of involved LN, size of primary tumor, histologic grade of tumor, presence of lymphatic vessel invasion (LVI), presence of an extensive intraductal component (EIC), radiation dose, use of adjuvant chemotherapy, and age of patient.
  • [MeSH-minor] Axilla. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Lymph Node Excision. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10656369.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


21. Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, Hunt KK, Whitman GJ, Stephens T, Buzdar AU, Green MC, Symmans WF: Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol; 2006 Nov;13(11):1443-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
  • BACKGROUND: Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning.
  • METHODS: Tumor size was evaluated by physical examination, mammography, and sonography at diagnosis and before surgery in 162 breast cancer patients who received neoadjuvant chemotherapy.
  • The effect of invasive lobular carcinoma, high nuclear grade, hormone receptor positivity, and the presence of an extensive intraductal component on the accuracy of mammography and sonography in predicting pathologic residual tumor size was analyzed.
  • Multivariate analysis showed that pathologic residual tumor size was underestimated for lobular carcinoma and overestimated for poorly differentiated tumors.
  • CONCLUSIONS: The combination of mammography and sonography has a high accuracy in predicting pCR after neoadjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / drug therapy. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028770.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


22. Siewinski M, Saleh Y, Gryboc M, Murawski M, Ekonjo GB, Ziólkowski P, Janocha A, Symonowicz K: Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E. J Exp Ther Oncol; 2004 Oct;4(3):189-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of cysteine peptidases-like activity and their inhibitors in the serum of patients with ovarian cancer treated by conventional chemotherapy and vitamin E.
  • The study was objected to the effects enhanced by taxol and cisplatin in patients pretreated with the vitamin E, by determining the levels of cathepsins B and L in sera of patients with ovarian cancer.
  • The activity of cysteine peptidase (CP) and their inhibitors (CPI) in serum from patients with ovarian cancer and noncancerous patients were measured by using fluorogenic substrate before and after the routine anticancer chemotherapy, and a complementary combination of chemotherapy with vitamin E.
  • The results shows that, inhibitory activity of CPI and complex form were significantly decreased from 4.6 mEU/mg protein in a group of non-cancerous patients to 0.7 mEU/mg protein in a group of patients with ovarian cancer (p < or = 0.0001).
  • Supplementation with vitamin E after a cycle of therapy with toxic drugs caused a decrease of the cysteine peptidases activities, that is 2.8-fold in patients to whom 40 0mg of vitamin E per day was given in comparison with control, and 6-fold after the third course.
  • The CPI and DCPI complex increased 3-fold and 2.3 fold respectively, as compared to a group of patients were vitamin E was not administered.
  • We observed that vitamin E administered to the patients with ovarian cancer in periods between anticancer drugs therapy courses decreases the cysteine peptidases activity and increases the enzyme-inhibitor complexes level
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antioxidants / pharmacology. Antioxidants / therapeutic use. Cathepsin B / pharmacology. Cathepsins / pharmacology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / enzymology. Vitamin E / pharmacology. Vitamin E / therapeutic use
  • [MeSH-minor] Adult. Cathepsin L. Cell Transformation, Neoplastic. Cisplatin / administration & dosage. Cysteine Endopeptidases. Drug Interactions. Enzyme Inhibitors / blood. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724838.001).
  • [ISSN] 1359-4117
  • [Journal-full-title] Journal of experimental therapeutics & oncology
  • [ISO-abbreviation] J. Exp. Ther. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Enzyme Inhibitors; 1406-18-4 / Vitamin E; EC 3.4.- / Cathepsins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.1 / Cathepsin B; EC 3.4.22.15 / CTSL1 protein, human; EC 3.4.22.15 / Cathepsin L; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Poonawalla T, Uchida T, Diven DG: Survey of antibiotic prescription use for inflamed epidermal inclusion cysts. J Cutan Med Surg; 2006 Mar-Apr;10(2):79-84
MedlinePlus Health Information. consumer health - Antibiotics.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Symptomatic epidermal inclusion cysts (EICs) are variously called "inflamed" or "infected," and the mechanism of inflammation or suppuration is controversial.
  • Whether physicians routinely prescribe antibiotics for inflamed EICs is of concern owing to cost and bacterial resistance.
  • OBJECTIVES: To determine whether there is any difference in the diagnosis and treatment of EICs between primary care physicians and dermatologists and to estimate the rate and cost of antibiotic prescriptions for EICs.
  • Eighty-four percent of the general practitioners and 94% of the dermatologists chose antibiotics for treatment.
  • CONCLUSION: This study shows that despite the differences between general practitioners and dermatologists in diagnosis, the majority of physicians use antibiotics for the treatment of inflamed EICs.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Drug Prescriptions / statistics & numerical data. Epidermal Cyst / drug therapy. Practice Patterns, Physicians' / statistics & numerical data
  • [MeSH-minor] Humans. Inflammation / drug therapy. Texas

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241579.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


24. Kang DK, Kim EJ, Kim HS, Sun JS, Jung YS: Correlation of whole-breast vascularity with ipsilateral breast cancers using contrast-enhanced MDCT. AJR Am J Roentgenol; 2008 Feb;190(2):496-504
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred three of these 143 patients were finally enrolled in the study after exclusion of patients with bilateral breast cancer, previous history of neoadjuvant chemotherapy, breast surgery, or lack of surgical confirmation.
  • Breast vascularity was then correlated to prognostic factors including tumor size, lymph node status, cancer stage, nuclear and histologic grade, presence of an extensive intraductal component, presence of hormone receptors, and expression of C-erb-B2.
  • The presence of extensive intraductal component and hormone receptors and the expression of C-erb-B2 were not related to ipsilateral increased vascularity.
  • [MeSH-major] Breast Neoplasms / blood supply. Breast Neoplasms / radiography. Neovascularization, Pathologic / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212238.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kugaevskaia EV: [Angiotensin converting enzyme domain structure and properties]. Biomed Khim; 2005 Nov-Dec;51(6):567-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiotensin converting enzyme domain structure and properties].
  • Angiotensin converting enzyme (ACE) is a key enzyme of the renin-angiotensin and kallikrein-kinin systems responsible for the regulation of blood pressure.
  • Recently the new physiological function of ACE has been revealed: the enzyme hydrolyses in vivo the natural peptide (N-AcSer-Asp-Lys-Pro), a negative regulator of hematopoietic stem cell proliferation.
  • Specific ACE inhibitors used for treatment of hypertension, inhibit both domains, but their dissociation rates of enzyme-inhibitor complex are different.
  • Selective binding of ACE inhibitors to either N- or C-domain may influence their biological effect during treatment.
  • [MeSH-minor] Angiotensin-Converting Enzyme Inhibitors / pharmacology. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Animals. Humans. Hypertension / drug therapy. Hypertension / physiopathology. Kallikreins / metabolism. Male. Protein Structure, Tertiary / physiology. Testis / enzymology

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521820.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.4.21.- / Kallikreins
  • [Number-of-references] 95
  •  go-up   go-down


26. Ascenzi P, Bocedi A, Bolognesi M, Spallarossa A, Coletta M, De Cristofaro R, Menegatti E: The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci; 2003 Jun;4(3):231-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein.
  • The pancreatic Kunitz inhibitor, also known as aprotinin, bovine basic pancreatic trypsin inhibitor (BPTI), and trypsin-kallikrein inhibitor, is one of the most extensively studied globular proteins.
  • BPTI reacts rapidly with serine proteases to form stable complexes, but the enzyme: inhibitor complex formation may involve several intermediates corresponding to discrete reaction steps.
  • Moreover, BPTI inhibits the nitric oxide synthase type-I and -II action and impairs K+ transport by Ca2+-activated K+ channels.
  • [MeSH-minor] Acute Disease. Amino Acid Sequence. Animals. Cattle. Chymotrypsin / antagonists & inhibitors. Kinetics. Models, Molecular. Pancreatitis / drug therapy. Protein Conformation. Protein Structure, Tertiary. Sequence Homology, Amino Acid. Serine Endopeptidases / metabolism. Thermodynamics. Trypsin Inhibitors / metabolism

  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • Hazardous Substances Data Bank. APROTININ .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12769721.001).
  • [ISSN] 1389-2037
  • [Journal-full-title] Current protein & peptide science
  • [ISO-abbreviation] Curr. Protein Pept. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Trypsin Inhibitors; 9087-70-1 / Aprotinin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.1 / Chymotrypsin
  • [Number-of-references] 193
  •  go-up   go-down


27. Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM: Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther; 2005 Aug;5(4):737-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 20-year follow-up results of two pioneering randomized controlled trials demonstrating equal survival after mastectomy and breast-conservation therapy, recent high-quality, evidence-based clinical practice recommendations have been made.
  • Breast-conservation therapy undoubtedly represents substantial progress for a better quality of life for women with early-stage breast cancer.
  • Risk factors for local failure include margin status, young age and an extensive intraductal component.
  • Young age and family history strongly suggest the need for genetic testing before initiation of treatment.
  • Women with BRCA1 or BRCA2 mutations should be informed about the increased risk of contralateral breast cancer and ipsilateral failure after breast-conservation therapy.
  • Bilateral mastectomy should also be offered as a treatment option.
  • There is controversy over whether current effective adjuvant treatment, including chemotherapy and endocrine therapy, beyond appropriate local treatment as surgery and radiotherapy, can improve local control.
  • Instead of debate over whether an ipsilateral tumor after breast-conservation therapy is local recurrence or a new primary cancer by analyzing conflicting data lacking strong evidence, efforts should be focused on reducing this risk irrespective of origin.
  • Selecting women for breast-conservation therapy and achieving margin control can reduce ipsilateral failures.
  • [MeSH-minor] Chemotherapy, Adjuvant. DNA Mutational Analysis. Female. Genes, BRCA1. Genes, BRCA2. Humans. Predictive Value of Tests. Prognosis. Radiotherapy, Adjuvant. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111473.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 68
  •  go-up   go-down


28. Du X, Guo C, Hansell E, Doyle PS, Caffrey CR, Holler TP, McKerrow JH, Cohen FE: Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J Med Chem; 2002 Jun 20;45(13):2695-707
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently there is an urgent need to develop antitrypanosomal therapy due to the toxicity of existing agents and emerging drug resistance.
  • We initially discovered that 3'-bromopropiophenone thio semicarbazone (1i) inhibited cruzain and could cure mammalian cell cultures infected with T. cruzi.
  • Kinetic studies show that these are time-dependent inhibitors.
  • Molecular modeling studies of the enzyme-inhibitor complex have led to a proposed mechanism of interaction as well as insight into the SAR of the thio semicarbazone series.
  • The nonpeptide nature of this series, small size, and extremely low cost of production suggest this is a promising direction for the development of new antitrypanosome chemotherapy.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12061873.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / 1F32 AI 10293-02; United States / NIAID NIH HHS / AI / AI 35707
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cysteine Proteinase Inhibitors; 0 / Protozoan Proteins; 0 / Thiosemicarbazones; 0 / Trypanocidal Agents; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.- / cruzain, Trypanosoma cruzi
  •  go-up   go-down


29. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, von Kummer R: Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke; 2006 Apr;37(4):973-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II.
  • BACKGROUND AND PURPOSE: The significance of early ischemic changes (EICs) on computed tomography (CT) to triage patients for thrombolysis has been controversial.
  • The Alberta Stroke Program Early CT Score (ASPECTS) semiquantitatively assesses EICs within the middle cerebral artery territory using a10-point grading system.
  • METHODS: Data from the European-Australian Acute Stroke Study (ECASS) II study were used in which 800 patients were randomized to recombinant tissue plasminogen activator (rt-PA) or placebo within 6 hours of symptom onset.
  • We performed a multivariable logistic regression analysis and assessed for an interaction between rt-PA treatment and baseline ASPECTS score.
  • There was no treatment-by-ASPECTS interaction with dichotomized ASPECTS (P=0.3).
  • However, a treatment-by-ASPECTS effect modification was seen in predicting PH (0.043 for the interaction term), indicating a much higher likelihood of thrombolytic-related parenchymal hemorrhage in those with ASPECTS < or =7.
  • [MeSH-major] Brain Ischemia / drug therapy. Brain Ischemia / radiography. Fibrinolytic Agents / therapeutic use. Tissue Plasminogen Activator / therapeutic use. Tomography, X-Ray Computed
  • [MeSH-minor] Aged. Cerebral Hemorrhage / chemically induced. Cerebral Hemorrhage / epidemiology. Female. Humans. Incidence. Injections, Intravenous. Male. Middle Aged. Middle Cerebral Artery / radiography. Predictive Value of Tests. Prognosis. Randomized Controlled Trials as Topic. Recombinant Proteins / administration & dosage. Recombinant Proteins / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497977.001).
  • [ISSN] 1524-4628
  • [Journal-full-title] Stroke; a journal of cerebral circulation
  • [ISO-abbreviation] Stroke
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents; 0 / Recombinant Proteins; EC 3.4.21.68 / Tissue Plasminogen Activator
  •  go-up   go-down


30. Sauer R, Schulz KD, Hellriegel KP, Deutsche Gesellschaft für Senologie]: [Radiation therapy after mastectomy--interdisciplinary consensus puts and end to a controversy. German Society of Senology]. Strahlenther Onkol; 2001 Jan;177(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiation therapy after mastectomy--interdisciplinary consensus puts and end to a controversy. German Society of Senology].
  • BACKGROUND: Recent publications of the Danish Breast Cancer Cooperative Group together with data from the British Columbia Trial have stirred major discussions concerning the role of radiation therapy after mastectomy.
  • Different treatment approaches are to be found even within the same cancer center.
  • The German Society of Senology, a cooperative group of all medical disciplines involved in the treatment of breast cancer, has therefore worked out a consensus statement.
  • MATERIAL AND METHOD: The recently published literature and experts opinions, in particular randomized studies since 1997, meta-analyses from the Early Breast Cancer Trialists' Collaborative Group, epidemiological investigations with regard to the time course of distant metastases in breast cancer as well as the current consensus of the American Society for Therapeutic Radiology and Oncology served as the basis for discussion and consulting.
  • If axillary lymph nodes are involved, the surgical removal of these lymph nodes is not only of diagnostic, but also of therapeutic value, as it reduces the risk for locoregional relapses. (2) Most probably, locoregional relapses do not only indicate, but are also a source for distant metastases. (3) Radiation therapy of the chest wall and the regional lymph nodes increases the overall survival in risk patients and reduces the risk of locoregional relapses.
  • Moreover, radiation therapy improves the prognosis in case of residual tumor or an incomplete axillary dissection.
  • Unequivocal and reasonable indications for radiation therapy after mastectomy include T3/T4-carcinoma, T2-carcinoma > 3 cm, multicentric tumor growth, lymphangiosis carcinomatosa or vessel involvement, involvement of the pectoralis fascia or a safety margin < 5 mm, R1- or R2 resection and more than 3 axillary lymph node metastases.
  • Further reasonable indications, albeit not yet evaluated in clinical trials, include multifocality, extensive intraductal component, negative hormone receptor status, G3-differentiation grade, diffuse micro-calcifications, 1 to 3 axillary lymph node metastases, multiple, non-complete biopsies and age < 35 years. (4) An endocrine therapy with tamoxifen concurrent to radiation therapy is also reasonable--despite some contradictory in-vitro data--as it enhances the apoptotic cell death.
  • The CMF-regimen is usually performed as sandwich procedure, but can also be applied concurrently to radiation therapy, if indicated.
  • Conversely, an anthracycline-containing chemotherapy should be finished prior to postoperative radiation therapy.
  • CONCLUSIONS: Adjuvant radiation therapy after mastectomy improves the 10-year-survival probability up to 10%, at least for risk patients.
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Neoplasm Metastasis. Prognosis. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11200107.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 64
  •  go-up   go-down


31. Schwartz PE: The management of serous papillary uterine cancer. Curr Opin Oncol; 2006 Sep;18(5):494-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of serous papillary uterine cancer.
  • PURPOSE OF REVIEW: Uterine papillary serous cancer is an extremely aggressive cancer, the optimum management of which is still being determined.
  • RECENT FINDINGS: The main themes in the literature regarding uterine papillary serous cancer are that a potential precursor lesion, serous endometrial intraepithelial carcinoma, has been recognized as an early form of the disease.
  • A variety of molecular biologically important markers have now been identified, including p53, HER2/neu, IL-6, kallikrein 6, and claudin-4, some of which may be susceptible to molecularly targeted therapy.
  • Systematic surgical staging is necessary before additional therapy is recommended.
  • Stage I uterine papillary serous cancer requires aggressive treatment, including surgery, chemotherapy, and radiation therapy for successful treatment.
  • SUMMARY: Serous endometrial intraepithelial carcinoma should be treated as a form of uterine papillary serous cancer.
  • Multimodality therapy is required for the successful management of early stage uterine papillary serous cancer.
  • Advanced disease is often unresponsive to conventional therapy.
  • Molecularly targeted therapies are now being introduced into the management of this disease.
  • [MeSH-major] Carcinoma, Papillary / therapy. Endometrial Neoplasms / therapy. Uterine Neoplasms / therapy


32. Perez CA: Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities. Cancer J; 2003 Nov-Dec;9(6):442-53
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservation therapy in T1-T2 breast cancer: past, current issues, and future challenges and opportunities.
  • PURPOSE: To assess the significance of patient age, race, tumor-related prognostic parameters, status of surgical excision margins, and irradiation boost on incidence of ipsilateral breast relapse, and to review current issues in the management of T1-T2 breast cancer patients with conservation therapy.
  • MATERIALS AND METHODS: Records of 1037 patients with histologically confirmed stage T1 and 308 patients with T2 carcinoma of the breast treated with breast conservation therapy from January 1970 through December 1997 were prospectively registered and evaluated.
  • In patients 40 years of age or younger, four of 24 (17%) with extensive intraductal component developed an ipsilateral breast relapse, compared with six of 80 (8%) without extensive intraductal component, in contrast to eight of 159 (5%) and 33 of 776 (4%) in postmenopausal patients with or without extensive intraductal component, respectively.
  • In patients with T2 tumors, two of eight (25%) women 40 years or younger with extensive intraductal component, and seven of 50 (14%) without extensive intraductal component developed ipsilateral breast relapse.
  • In patients with positive margins, the relapse rate was 4% in 215 receiving a boost (18-20 Gy) and 33% (two of six) without a boost.
  • In T1 tumors, the breast failure rate was two of 53 (3.7%) in women < or = 40 years receiving chemotherapy and eight of 51 (15.6%) without chemotherapy.
  • On multivariate analysis, only age and adjuvant therapy were significant factors predictive of ipsilateral breast relapse.
  • CONCLUSIONS: Surgical excision margins status following adequate doses of radiation therapy was not a predictor of ipsilateral breast relapse.
  • In patients younger than 40 years of age with extensive intraductal component, a somewhat higher breast relapse rate was noted but not enough to preclude breast conservation therapy.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal / surgery. Mastectomy, Segmental / trends. Neoplasm Recurrence, Local / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14740972.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] United States
  •  go-up   go-down


33. Perera F, Yu E, Engel J, Holliday R, Scott L, Chisela F, Venkatesan V: Patterns of breast recurrence in a pilot study of brachytherapy confined to the lumpectomy site for early breast cancer with six years' minimum follow-up. Int J Radiat Oncol Biol Phys; 2003 Dec 1;57(5):1239-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between March 1992 and January 1996, 39 patients with T1 (32 patients) and T2 breast cancers received 37.2 Gy in 10 fractions (b.i.d.) over 1 week prescribed to a volume encompassing the surgical clips.
  • Thirteen received adjuvant tamoxifen, and 4 received chemotherapy.
  • One of the 2 patients had a 1-mm microscopic margin at initial diagnosis; the recurrence was a 3.5-mm microscopic focus of duct carcinoma in situ.
  • The other patient had a 1.5-cm, high-grade infiltrating mammary carcinoma with no residual at wider resection at first diagnosis; the 5-mm invasive recurrence was also of high grade.
  • Four women developed invasive recurrences at least 1.6 cm or more from the lumpectomy site (out-of-field recurrences).
  • Two of these women had gross multifocal recurrences with two cancers in each patient; 1 of the 2 patients had an extensive intraductal component at initial diagnosis.
  • Of 17 patients who received adjuvant systemic therapy, only 1 had a breast recurrence.
  • [MeSH-major] Brachytherapy / methods. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / radiotherapy. Carcinoma, Intraductal, Noninfiltrating / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma in Situ / surgery. Chemotherapy, Adjuvant. Dose Fractionation. Female. Follow-Up Studies. Humans. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Pilot Projects. Salvage Therapy. Treatment Failure

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1214-6 [14630253.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1210-3 [14630252.001]
  • (PMID = 14630257.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Dimitropoulos N, Papakyriakou A, Dalkas GA, Sturrock ED, Spyroulias GA: A computational approach to the study of the binding mode of dual ACE/NEP inhibitors. J Chem Inf Model; 2010 Mar 22;50(3):388-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combined blockade of the renin-angiotensin-aldosterone system (RAAS) is an attractive therapeutic strategy for the treatment of cardiovascular diseases.
  • Vasopeptidase inhibitors are a group of compounds capable of inhibiting more than one enzyme, which leads to potentiation of natriuretic peptide actions and suppression of the RAAS.
  • In this study, molecular modeling has been used to elucidate key structural features that govern the binding and/or selectivity of a single compound toward the zinc catalytic sites of the N- and C-domains of the angiotensin-converting enzyme (ACE) and the neutral endopeptidase (NEP).
  • Residues that were identified to actively participate in the binding and stabilizing of the enzyme-inhibitor complexes were analyzed in a consensus way for both the ACE and the NEP.
  • These atomic-level insights into enzyme-ligand binding can be used to drive new structure-based drug design processes in the quest for more selective and effective vasopeptidase inhibitors.
  • [MeSH-major] Angiotensin-Converting Enzyme Inhibitors / chemistry. Angiotensin-Converting Enzyme Inhibitors / pharmacology. Neprilysin / metabolism. Peptidyl-Dipeptidase A / metabolism. Protease Inhibitors / chemistry. Protease Inhibitors / pharmacology
  • [MeSH-minor] Binding Sites. Cardiovascular Diseases / drug therapy. Humans. Models, Molecular. Protein Binding. Renin-Angiotensin System / drug effects. Structure-Activity Relationship

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20170101.001).
  • [ISSN] 1549-960X
  • [Journal-full-title] Journal of chemical information and modeling
  • [ISO-abbreviation] J Chem Inf Model
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Protease Inhibitors; EC 3.4.15.1 / Peptidyl-Dipeptidase A; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


35. Irvin WP, Rice LW, Berkowitz RS: Advances in the management of endometrial adenocarcinoma. A review. J Reprod Med; 2002 Mar;47(3):173-89; discussion 189-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the management of endometrial adenocarcinoma. A review.
  • Endometrial adenocarcinoma is the most common and curable gynecologic neoplasm; the five-year survival for women with surgical stage I disease ranges from 83% to 93%; stage II, 73%; stage III, 52%; and stage IV, 27%.
  • The absence of an asymptomatic latency phase amenable to detection through screening and the already excellent cure rates seen with early-stage disease have precluded the need for endometrial cancer screening programs.
  • Adenocarcinomas constitute 97% of endometrial cancers, with endometrioid the most common histologic subtype.
  • Two different pathways of endometrial carcinogenesis exist.
  • The use of oral contraceptives has consistently been shown to decrease the risk of developing endometrial carcinoma via this pathway, with 12 months or more of continuous use decreasing the lifetime risk by 40-50%.
  • The alternate pathway of endometrial carcinogenesis represents malignant transformation of atrophic endometrium and proceeds through endometrial intraepithelial carcinoma as the malignant precursor of the more virulent serous papillary and clear cell endometrial adenocarcinomas.
  • The staging of endometrial cancer (according to the International Federation of Obstetrics and Gynecology) is surgical.
  • Recent studies suggest a therapeutic benefit associated with extensive retroperitoneal lymph node evaluation to determine the disease extent and thereby more effectively direct potentially life-saving adjuvant therapy.
  • Adjuvant radiation therapy, known to have survival benefit in advanced-stage disease, may also have survival benefit in intermediate-risk surgical stage I disease on the basis of results recently released from a Gynecologic Oncology Group study.
  • The use of radiation therapy, systemic chemotherapy and hormonal therapy, alone or in combination, is recommended for primary advanced and recurrent disease.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Endometrial Neoplasms / radiotherapy. Endometrial Neoplasms / surgery. Neoplasm Staging
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Incidence. Radiotherapy, Adjuvant. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11933681.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 126
  •  go-up   go-down


36. Wang YM, Song HY, Tong Z, Qian SJ, Guo RX, Jing ZJ, Shi JR: [Effects of er-long-zuo-ci-wan on the spontaneous activities of auditory central nucleus in rat model of tinnitus induced by salicylate acid]. Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2009 Aug;25(3):397-401
Hazardous Substances Data Bank. SALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of er-long-zuo-ci-wan on the spontaneous activities of auditory central nucleus in rat model of tinnitus induced by salicylate acid].
  • AIM: Observe the effects of er-long-zuo-ci-wan (EIZCW, a compound of Chinese Traditional Medicine) on the spontaneous discharge of external cortex of inferior colliculus (ICx) and secondary auditory cortex (AII) of chronic tinnitus model rats induced by salicylate acid, to explore the neural mechanisms underlying ELZCW preventing tinnitus.
  • [MeSH-major] Auditory Cortex / physiopathology. Auditory Pathways / drug effects. Drugs, Chinese Herbal / pharmacology. Phytotherapy. Tinnitus / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Tinnitus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21155246.001).
  • [ISSN] 1000-6834
  • [Journal-full-title] Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
  • [ISO-abbreviation] Zhongguo Ying Yong Sheng Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; O414PZ4LPZ / Salicylic Acid
  •  go-up   go-down






Advertisement